| Overview |
| bs-6065r-100ul |
| TCF3 Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TCF3/E2A |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 6929 |
| Intracellular |
| bHLHb21; Class B basic helix-loop-helix protein 21; E12; E2A; E2A immunoglobulin enhancer binding factors E12/E47; E47; Helix loop helix protein HE47; Immunoglobulin enhancer-binding factor E12/E47; immunoglobulin transcription factor 1; ITF1; Kappa E2 binding factor; Kappa-E2-binding factor; MGC129647; MGC129648; Negative vitamin D response element binding protein; TCF-3; TCF3; TFE2; TFE2_HUMAN; transcription factor 3; Transcription factor E2-alpha; Transcription factor ITF-1; VDIR; VDR interacting repressor. |
| Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |